|本期目录/Table of Contents|

[1]侯岩君,韩育宁,马云帆,等.SHOX2基因启动子甲基化与肺癌关系的Meta分析[J].宁夏医科大学学报,2019,(12):1211-1216.[doi:10.16050/j.cnki.issn1674-6309.2019.12.005]
 HOU Yanjun,HAN Yuning,MA Yunfan,et al.A Meta-analysis of Association between SHOX2 Gene Promoter Methylation and Lung Cancer[J].Ningxia Medical University,2019,(12):1211-1216.[doi:10.16050/j.cnki.issn1674-6309.2019.12.005]
点击复制

SHOX2基因启动子甲基化与肺癌关系的Meta分析(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2019年12期
页码:
1211-1216
栏目:
论著
出版日期:
2020-03-27

文章信息/Info

Title:
A Meta-analysis of Association between SHOX2 Gene Promoter Methylation and Lung Cancer
文章编号:
1674-6309(2019)12-1211-06
作者:
侯岩君1 韩育宁2 马云帆2 胡立夫34 Nawaz Imran345
(1. 宁夏医科大学,银川 750004; 2. 宁夏医科大学总医院普胸外科,银川 750004; 3. 卡罗林斯卡医学院微生物、 肿瘤和细胞生物学系,斯德哥尔摩 17177,瑞典; 4. 深圳市人民医院胸外科,深圳 518000; 5. 巴洛奇斯坦大学 微生物学系,奎达 87300,巴基斯坦)
Author(s):
HOU Yanjun1 HAN Yuning2 MA Yunfan2 HU Lifu34 Nawaz Imran345
(1. Ningxia Medical University,Yinchuan 750004, China; 2. Department of Thoracic Surgery,General Hospital of Ningxia Medical University,Yinchuan 750004,China; 3. Department of Microbiology,Tumor and Cell Biology,Karolinska Institute,Stockholm 17177,Sweden; 4. Department of thoracic surgery,Shenzhen peoples hospital,Shenzhen 518000,China; 5. Department of Microbiology,University of Balochistan,Quetta 87300,Pakistan)
关键词:
肺癌甲基化SHOX2基因Meta分析
Keywords:
lung cancer methylationSHOX2 gene meta analysis
分类号:
R734.2
DOI:
10.16050/j.cnki.issn1674-6309.2019.12.005
文献标志码:
A
摘要:
目的 通过Meta分析的方法探讨SHOX2基因启动子甲基化与肺癌的关系。方法 全面检索中国知网、万方医学数据库、维普中文期刊、Pubmed、Web of science等数据库,查找有关SHOX2基因启动子甲基化与肺癌关系的临床研究文献。搜索期限为2018年12月31日之前。应用Stata14.0软件对所得数据进行Meta分析。结果 研究共纳入14篇文献,其中实验组肺癌标本1671例,对照组标本1659例,纳入最后统计数据,Meta分析结果表明,肺癌患者肿瘤组织中SHOX2基因甲基化出现的阳性风险明显高于对照组,用患者正常的肺组织标本为参照,其OR值合并效应量为18.54(95%CI:11.20~30.69,P<0.05),即肿瘤组织出现阳性的风险是对照组的18.54倍。按样本种类进行亚组分析,组织样本中OR值为33.94(95%CI:13.42~85.85,P<0.05);血浆样本中OR值为11.37(95%CI:4.33~29.84,P<0.05),灌洗液样本中OR值为24.58(95%CI:12.77~47.32,P<0.05);胸腔积液样本中OR值为5.52(95%CI:3.92~7.78,P<0.05);将纳入文献的肺恶性肿瘤的病理学类型进行亚组分析结果显示,腺癌所占比例(腺癌/腺癌+鳞癌+其他类型)小于25%以下OR值为12.33(95%CI:6.68~22.76,P<0.05),腺癌所占比例大于25%以上OR值为38.07(95%CI:17.98~80.60,P<0.05);将纳入文献的肺恶性肿瘤临床分期进行亚组分析结果表明,Ⅲ和Ⅳ期所占比例小于65%以下OR值为21.65(95%CI:11.80~39.73,P<0.05),Ⅲ和Ⅳ期所占比例大于65%以上OR值为20.34(95%CI:3.39~121.91,P<0.05)。结论 肺癌患者肺癌组织中SHOX2基因启动子甲基化增高,此基因启动子甲基化和肺癌的发生可能存在相关性;SHOX2基因启动子甲基化和肺腺癌存在相关性,但与患者的临床分期无明显相关性。
Abstract:
Objective To evaluate the relationship between SHOX2 gene promoter methylation and lung cancer risk by meta-analysis. Methods A comprehensive search of CNKI, Wanfang Medical Database, VIP, Pubmed,Web of Science and other databases to find a clinical research literature on the relationship between SHOX2 gene promoter methylation and lung cancer. The search period is before December 31,2018.Meta-analysis of the data was performed using Stata 14.0 software. Results A total of 14 articles were included in the study. Among them,1671 cases of lung cancer specimens in the experimental group and 1659 specimens in the control group were included in the final statistical data. The results of meta-analysis showed that the positive risk of SHOX2 gene methylation in tumor tissues of lung cancer patients was significantly higher than (下转第1221页)(上接第1216页)that of the control group. The patient's normal lung tissue specimens were used as reference. The combined effect of the OR value was 18.54 (95%CI: 11.20 to 30.69, P<0.05), the risk of tumor tissue positive was 18.54 times that of the control group. Subgroup analysis was performed according to the sample type. The OR value of the tissue samples was 33.94 (95%CI: 13.42 to 88.55, P<0.05). The OR value of plasma samples was 11.37 (95%CI: 4.33 to 29.84,P<0.05). The OR value of the lavage fluid sample was 24.58(95%CI: 12.77 to 47.32, P<0.05); the OR value of the pleural effusion sample was 5.52(95%CI: 3.92 to 7.78,P<0.05). Subgroup analysis of pathological types of lung malignant tumors showed that the proportion of adenocarcinoma adenocarcinoma/ adenocarcinoma+squamous cell carcinoma+other types) was less than 25% and the OR value was 12.33(95%CI: 6.68 to 2.76,P<0.05), the proportion of adenocarcinoma was more than 25% and the OR value was 38.07 (95%CI: 17.98 to 80.60,P<0.05). The clinical stage of lung malignant tumors included in the literature was analyzed by subgroup. The results showed that: The proportion of the period and the fourth period (Ⅲ phases + Ⅳ phases / Ⅰ phase + Ⅱ phases + Ⅲ phases + Ⅳ phases) less than 65% below the OR value of 21.65(95%CI: 11.80 to 39.73, P<0.05), Ⅲ phases The ratio of the Ⅳ phase to the fourth phase was greater than 65% and the OR value was 20.34(95% CI: 3.39 to 121.91, P<0.05). Conclusion The methylation of SHOX2 gene promoter is increased in lung cancer tissue, which may be related to the occurrence of lung cancer; the methylation of SHOX2 gene promoter is related to lung adenocarcinoma,but not to the clinical stage.

参考文献/References:

[1] Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[2] 邹小农,贾漫漫, 王鑫, 等. 中国肺癌和烟草流行及控烟现状[J]. 中国肺癌杂志,2017,20(8):505-510.
[3] Risch A,Plass C. Lung cancer epigenetics and genetics[J]. Int J Cancer,2008,123(1):1-7.
[4] Ilse P,Biesterfeld S,Pomjanski N,et al. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis[J]. Cancer Genomics Proteomics,2014,11(5):251-258.
[5] Nawaz I,Qiu XM,Wu H,et al. Development of a multiplex methylation specific PCR suitable for (early) detection of non-small cell lung cancer[J]. Epigenetics,2014,9(8):1138-1148.
[6] 容秋萍. 非小细胞肺癌SHOX2基因甲基化的诊断意义及其临床特征[D]. 广东:广东医学院,2016.
[7] 王南,李卓伦,谢昕,等. 肺癌患者血浆SHOX2基因甲基化微滴数字PCR检测临床意义[J]. 中华肿瘤防治杂志,2018,25(17):1241-1246.
[8] 张毅敏,王明丽,吴杰,等. 肺泡灌洗液中SHOX2和RASSF1A基因甲基化联合检测对肺癌的诊断价值[J]. 肿瘤学杂志,2016,22(12):1032-1036.
[9] Ren MP,Wang CH,Sheng DL,et al. Methylation analysis of SHOX2 and RASSF1A in bronchoalveolar lavage fluid for early lung cancer diagnosis[J]. Ann Diagn Pathol,2017,27:57-61.
[10] Schneider KU,Dietrich D,Fleischhacker M,et al. Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors[J]. BMC Cancer,2011, 11:102.
[11] Schmidt B,Liebenberg V,Dietrich D,et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates[J]. BMC Cancer,2010,10:600.
[12] Kneip C,Schmidt B,Seegebarth A,et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma[J]. J Thorac Oncol,2011,6(10):1632-1638.
[13] Dietrich D,Kneip C,Raji O,et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates[J]. Int J Oncol,2012,40(3):825-832.
[14] Konecny M,Markus J,Waczulikova I,et al. The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders[J]. Neoplasma,2016,63(2): 246-253.
[15] 王春华. 支气管肺泡灌洗液SHOX2、RASSF1A甲基化检测在肺癌诊断中的研究[D]. 杭州:浙江大学,2017.
[17] Ilse P,Biesterfeld S,Pomjanski N,et al. SHOX2 DNA methylation is a tumour marker in pleural effusions[J]. Cancer Genomics Proteomics,2013,10(5):217-223.
[18] Dietrich D,Jung M,Puetzer S,et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methy- lation and cytology in benign,paramalignant and malignant pleural effusions[J]. PLoS One,2013,8(12):e84225.
[19] Liu D,Peng HL,Sun Q,et al. The indirect efficacy comparison of DNA methylation in sputum for early screening and auxiliary detection of lung cancer: a meta-analysis[J]. Int J Environ Res Public Health,2017,14(7): E679.
[20] Huang T,Li JY,Zhang C,et al. Distinguishing lung adenocarcinoma from lung squamous cell carcinoma by two hypomethylated and three hypermethylated genes:a meta-analysis[J]. PLoS One,2016,11(2):e0149088.
[21] Semaan A,van Ellen A,Meller S,et al. SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocar- cinomas[J]. Clin Epigenetics,2016,8:100.

相似文献/References:

[1]吴敏良,马云帆,于 亮,等.上皮型钙黏蛋白在原发性非小细胞肺癌中表达的临床研究[J].宁夏医科大学学报,2012,(05):499.
[2]周丽萍,马科,马治国,等.健脾补肾方对小鼠Lewis肺癌抑制作用及对VEGF、CD44V6表达的影响[J].宁夏医科大学学报,2012,(04):319.
 ZHOU Li-ping,MA Ke,MA Zhi-guo,et al.[J].Ningxia Medical University,2012,(12):319.
[3]崔丽萍,张 锦,尹 梅,等.血清骨桥蛋白水平与非小细胞肺癌预后的相关性[J].宁夏医科大学学报,2012,(03):248.
 CUI Li-ping,ZHANG Jin,YIN Mei,et al.Relationship between Serum Osteopontin Levels and Prognosisin Non-small Cell Lung Cancer[J].Ningxia Medical University,2012,(12):248.
[4]马治国,马 科,周丽萍,等.回药爱康方协同化疗对小鼠Lewis肺癌细胞超微结构的影响[J].宁夏医科大学学报,2012,(03):201.
 MA Zhi-guo,MA Ke,ZHOU Li-ping,et al.Effective of Hui Medicine AikangFang Synergism Chemotherapyto Lewis Lung Carcinoma Cell Ultrastructure[J].Ningxia Medical University,2012,(12):201.
[5]丁志刚,梁华.左肺上叶切除肺动脉破裂大出血抢救成功1例[J].宁夏医科大学学报,2013,(08):952.
[6]郭 克,扈启宽.小鼠癫痫持续状态时组蛋白H3K9二甲基化水平 的变化及其调控作用[J].宁夏医科大学学报,2013,(07):748.
 GUO Ke,HU Qi-kuan.Alteration of Dimethylation Level of Histone 3 Lysine 9 during Status Epilepticus and Its Impact in Mice[J].Ningxia Medical University,2013,(12):748.
[7]李 录,贾绍斌.DNA甲基化与动脉粥样硬化的研究进展[J].宁夏医科大学学报,2013,(05):598.
[8]马云帆,吴敏良,韩育宁,等.EGFL7在原发性非小细胞肺癌中的表达研究[J].宁夏医科大学学报,2013,(04):431.
[9]王雪梅,石 华,杨露露,等.能谱CT定量分析在鉴别诊断肺鳞癌与腺癌中的应用价值[J].宁夏医科大学学报,2013,(04):415.
 WANG Xue-mei,SHI Hua,YANG Lu-lu,et al.Value of Spectral CT Imaging in Differentiating Plumonary Squamous Cell Carcinoma and Adenocarcinoma[J].Ningxia Medical University,2013,(12):415.
[10]杨文静,王宁菊,陈冬梅.XRCC1-194突变、RRM1-37多态性与晚期NSCLC 患者含铂方案化疗效果的相关性研究[J].宁夏医科大学学报,2013,(01):13.
 YANG Wen-jing,WANG Ning-ju,CHEN Dong-mei.Mutation in XRCC1,Polymorphism in RRM1 and Efficacy of Platin-based Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer[J].Ningxia Medical University,2013,(12):13.

备注/Memo

备注/Memo:
收稿日期:2019-04-07
基金项目:深圳市海外高层次人才创新创业专项资金(KQTD2016 113015442590)
作者简介:侯岩君,男,内蒙古人,在读硕士研究生,研究方向:肺癌甲基化。
通信作者:韩育宁,男,主任医师,硕士研究生导师。 E-mail: nxhyuning@163.com
更新日期/Last Update: 2019-12-30